19 results about "Platelet production" patented technology

The invention relates to the field of biological medicine, and provides an application of a dihydroorotate dehydrogenase inhibitor in preparation of megakaryocytes, and the dihydroorotate dehydrogenase inhibitor is a compound shown as a formula I, a formula II or a formula III, or a pharmaceutically acceptable salt of the compound. According to the technical scheme, the dihydroorotate dehydrogenase inhibitor can promote hematopoietic stem / progenitor cells to differentiate into megakaryocytes and platelets, the platelet generation amount is increased by about 2 times, and a promising strategy is provided for in-vivo and in-vitro megakaryocyte and platelet generation.

The utility model discloses a cell culture device. The cell culture device comprises a tank body mounting structure, a stirring assembly, a controller and a cell culture tank, the tank body mounting structure comprises a supporting frame, a weighing module and a tank body mounting frame; the support frame is provided with a bearing end surface and a mounting part; the weighing module is arranged on the bearing end surface; the tank body mounting frame is arranged on the weighing module, the cell culture tank is mounted on the tank body mounting frame, and the cell culture tank is connected with a first pipeline and a second pipeline; the stirring assembly comprises stirring blades, a stirring shaft and a driving mechanism, the stirring blades are arranged in the cell culture tank, one end of the stirring shaft is connected with the stirring blades, and the other end of the stirring shaft is connected with the driving mechanism; and the controller is connected with the driving mechanism, the weighing module and the control valves on the first pipeline and the second pipeline. Through the arrangement, a stable vortex shear force is formed in the cell culture tank, natural flow of blood in a human body is simulated, and a proper mechanical environment is provided for megakaryocyte culture and platelet production.

The present disclosure relates to the field of biological medicine, and provides a use of a dihydroorotate dehydrogenase inhibitor in the preparation of megakaryocytes, wherein the dihydroorotate dehydrogenase inhibitor is a compound represented by formula I, formula II or formula III, or a pharmaceutically acceptable salt of the compound. The dihydroorotate dehydrogenase inhibitor in the technical solution of the present disclosure can promote the differentiation of hematopoietic stem / progenitor cells into megakaryocytes and platelets, and increase the platelet production by about 2 times, thereby providing a promising strategy for the production of megakaryocytes and platelets in vivo and in vitro.

This disclosure provides the use of valbenazine, its active metabolites, or pharmaceutically acceptable salts thereof in the preparation of megakaryocytes, wherein the preparation of megakaryocytes is carried out in vitro. The valbenazine, its active metabolites, or pharmaceutically acceptable salts thereof in this disclosure can promote megakaryocyte proliferation and platelet production, providing a promising strategy for megakaryocyte proliferation and platelet production.

This invention relates to the field of biomedicine, specifically to the application of banana fruit extract in the preparation of anticoagulant or antithrombotic drugs. The banana fruit extract provided by this invention contains flavonoids, polyphenols, polysaccharides, hydroxyanthraquinones, triterpenoids, and other components. Flavonoids and polyphenols have been widely proven to have anti-inflammatory and antioxidant effects, which can synergistically enhance the anticoagulant effect. The high potassium content of banana fruit can indirectly improve vascular function by regulating sodium-potassium balance. The banana fruit extract provided by this invention can inhibit platelet production or promote platelet metabolism, prolong clotting time, and inhibit platelet aggregation. Its natural plant components interfere with platelet aggregation by inhibiting the production of thromboxane A2, achieving anticoagulant and antithrombotic effects. The mechanism of action of banana fruit extract differs from traditional anticoagulants such as heparin, reducing the risk of bleeding. Its natural component characteristics provide a direction for the development of novel plant-derived anticoagulant drugs.

The invention relates to a method for promoting megakaryocyte to generate platelets in vitro. Specifically, the invention provides a method for producing platelets by culturing megakaryocytes in stages, and the megakaryocytes are subjected to maturation and differentiation culture by adopting two culture mediums with different components, so that the quantity of platelets produced by in-vitro megakaryocytes is remarkably increased, and the motility rate of platelets produced by in-vitro megakaryocytes and the positive proportion of CD41 + / CD42b + are increased. In addition, components of the culture medium in the first stage are explored and optimized, and the culture medium capable of remarkably promoting megakaryocyte maturation is obtained. The culture method disclosed by the invention can be used for producing platelets in vitro in a high-quality and high-yield manner, and has a wide application prospect.

Methods of production and apparatuses for production for stably producing healthy and functional platelets, and methods for determining operating conditions of an apparatus for producing platelets are provided. The present invention relates to methods of production comprising a step of culturing megakaryocytes in a platelet production medium C, wherein the step of culturing comprises a step of stirring a medium C in containers 1, 4 using stirring mechanisms 2, 5. In one method of production, the step of stirring comprises reciprocating stirring blades 21, 24 in the stirring mechanisms 2, 24 such that any of predetermined turbulent energy, shearing stresses, or Kolmogorov scale is produced, in the medium C. In another method of production, the step of stirring comprises pivoting a stirring blade 51 in the stirring mechanism 5 wherein a plurality of stationary members 53 is placed therearound in a bottom region 4e of the container 4 such that the step of stirring produces turbulence in the medium C. The present invention also relates to apparatuses for production for carrying out the method of production. The present invention also relates to a method for determining operating conditions of an apparatus for producing platelets.

The present application relates to a method for promoting megakaryocytes to produce platelets in vitro. Specifically, the present application provides a method for producing platelets by culturing megakaryocytes in stages, using two culture media with different compositions for maturation and differentiation of megakaryocytes, which significantly improves the number of platelets produced by megakaryocytes in vitro, and improves the activity and CD41+ / CD42b+ positive proportion of megakaryocytes producing platelets in vitro. In addition, the composition of the first stage culture medium is explored and optimized to obtain a culture medium that can significantly promote the maturation of megakaryocytes. The culture method of the present application can be used to produce platelets in vitro with high quality and high yield, and has a wide application prospect.

The present invention relates to a novel anti-C-MPL antibody and a use thereof, and specifically, to an anti-C-MPL antibody having an effect of increasing platelet production and its number through the maturation of megakaryocytes in the bone marrow, and a use thereof. The novel anti-C-MPL antibody (2R13) of the present invention is a polymer material and has a longer half-life than the conventional therapeutic agents, and it has the advantage of low self-antibody production and low immunogenicity as an antibody agent. In addition, it can be used as a therapeutic agent for thrombocytopenia by increasing the platelet level of patients suffering from chronic or complication-induced immune thrombocytopenia.

The present application relates to a method for improving the quality of platelets produced in vitro. Specifically, the present inventors provide a platelet culture medium for in vitro culture, which can significantly improve the yield and quality of platelets cultured in vitro by optimizing the ingredients and adding new ingredients. Specifically, the viability of platelets obtained by culturing megakaryocytes in the culture medium of the present application and the proportion of CD42b+ cells are significantly increased, and the number of platelets produced by a single megakaryocyte is also significantly increased. The present application improves the problems of imperfect platelet function and unstable quality in existing in vitro platelet production technology, provides a stable platelet source for clinical transfusion, and has a wide application prospect.

One aspect relates to: olsalkene; a preparation method therefor; a composition for preventing or treating thrombocytopenia, comprising same; and use thereof. According to one aspect, it has been identified that olsalkene is not cleaved by azoreductase (AzoR) and binds to biliverdin reductase (BLVRB) in the body, thereby inhibiting the reduction of biliverdin (BV) to bilirubin (BR). In addition, it has been identified that platelet production is promoted through the inhibition of biliverdin reductase B activity. Therefore, the olsalkene can be effectively used as a therapeutic agent for thrombocytopenia or as a health functional food through the role of promoting platelet production by inhibiting the activity of biliverdin reductase B.

This invention relates to the field of platelet production technology, and in particular to a method for producing platelets based on biomimetic microcarriers. The method overcomes the key bottlenecks of low in vitro platelet yield, incomplete function, and difficulty in large-scale production in the prior art. By constructing a biomimetic bone marrow-vascular wall microenvironment, it systematically solves the technical problem of low yield of megakaryocytes in in vitro culture systems, and provides a brand-new solution for the safe, efficient, and economical in vitro preparation of platelets.

The invention provides application of valbenazine, an active metabolite of valbenazine or a medicinal salt of valbenazine in preparation of megakaryocytes. The megakaryocytes are prepared in vitro to prepare the megakaryocytes. The valbenazine, the active metabolite of the valbenazine or the medicinal salt of the valbenazine in the technical scheme can promote megakaryocyte proliferation and platelet production, and a promising strategy is provided for megakaryocyte proliferation and platelet production.

The invention relates to a method for improving the quality of platelets produced in vitro. Specifically, the inventor provides the in-vitro culture platelet culture medium, and the yield and the quality of the in-vitro culture platelet can be remarkably improved by optimizing components and adding novel components. Specifically, when megakaryocytes are cultured by adopting the culture medium disclosed by the invention, the motility rate of obtained platelets and the proportion of CD42b + cells are remarkably increased, and the number of platelets generated by a single megakaryocyte is also remarkably increased. According to the invention, the problems of incomplete platelet function, unstable quality and the like in the existing in-vitro platelet production technology are solved, a stable platelet source is provided for clinical infusion, and the application prospect is wide.

The invention provides a platelet production device and method, and relates to the field of medical instruments.The platelet production device comprises a reactor and a power device, the reactor comprises a reactor body and a sintered metal filter element, the power device comprises a first pipeline and a pump body connected with the first pipeline, and the two ends of the first pipeline are both arranged in the reactor body; wherein one end is connected with the sintered metal filter element. The platelet production device is low in production cost and beneficial to amplification, and the quality of produced platelets is greatly improved.

The invention relates to the field of human and veterinary medicine, and more particularly to a pharmaceutical composition for use as an agent for enhancing the ability to tolerate radiotherapy and also for providing a therapeutic effect after radiation exposure. The claimed pharmaceutical composition for use as an agent for enhancing a cancer patient's ability to tolerate radiotherapy and also for providing a therapeutic effect for humans or animals after radiation exposure comprises poloxamer 188 as a pharmacologically active agent, and at least one excipient. Proposed are variants of the pharmaceutical composition for use as a radiomitigator, the qualitative composition of which provides for a beneficial effect on bone marrow by preventing fatty infiltration and supporting de novo platelet production.

The invention provides application of adipose-derived stem cell artificial nano-vesicles in preparation of drugs for promoting platelet generation. The invention also provides an adipose-derived stem cell artificial nano-vesicle loaded with a sanguisorba monomer DMAG, and the adipose-derived stem cell artificial nano-vesicle is prepared by extracting a cell membrane of adipose-derived stem cells and entrapping DMAG by using a natural phospholipid bilayer structure of the cell membrane so as to form a nano-sized vesicle structure. The artificial nano-vesicle inherits good biocompatibility of adipose-derived stem cells, can effectively reduce immunological rejection of an organism, and protects DMAG from degradation effects such as in-vivo enzymolysis and the like; and a protective delivery system can be formed in vivo, so that rapid metabolism and elimination of DMAG in vivo are reduced, and the effective release time of DMAG in vivo is prolonged. The artificial nano-vesicles significantly increase the number of peripheral blood platelets, shorten the bleeding time and reduce the immunogenicity at the same time.